Isbn: 9789811070129 - hormone therapy and castration resistance of prostate cancer (3 Ergebnisse)

ISBN
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (3)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

    • Sprache: Englisch

      Verlag: Springer, 2018

      9811070121 / 9789811070129

      • Hardcover

      Anbieter: WeBuyBooks, Rossendale, LANCS, Vereinigtes KönigreichWeBuyBooks

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Gebraucht - Wie neu

      EUR 53,86

      EUR 11,66 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: 5 verfügbar

      Zustand: Like New. Most items will be dispatched the same or the next working day. An apparently unread copy in perfect condition. Dust cover is intact with no nicks or tears. Spine has no signs of creasing. Pages are clean and not marred by notes or folds of any kind.

    • Sprache: Englisch

      Verlag: Springer, 2018

      9811070121 / 9789811070129

      • Hardcover

      Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 237,34

      EUR 14,58 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: 1 verfügbar

      Hardcover. Zustand: Brand New. 433 pages. 9.25x6.10x0.94 inches. In Stock.

    • Sprache: Englisch

      Verlag: Springer Nature Singapore, 2018

      9811070121 / 9789811070129

      • Hardcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 224,71

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnicvariation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.